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Abstract
LZAP (Cdk5rap3, C53) is a putative tumor suppressor that inhibits RelA, Chk1 and Chk2 and activates p53. LZAP is lost in a
portion of human head and neck squamous cell carcinoma and experimental loss of LZAP expression is associated with
enhanced invasion, xenograft tumor growth and angiogenesis. p38 MAPK can increase or decrease proliferation and cell
death depending on cellular context. LZAP has no known enzymatic activity, implying that its biological functions are likely
mediated by its protein-protein interactions. To gain further insight into LZAP activities, we searched for LZAP-associated
proteins (LAPs). Here we show that the LZAP binds p38, alters p38 cellular localization, and inhibits basal and cytokine-
stimulated p38 activity. Expression of LZAP inhibits p38 phosphorylation in a dose-dependent fashion while loss of LZAP
enhances phosphorylation and activation with resultant phosphorylation of p38 downstream targets. Mechanistically, the
ability of LZAP to alter p38 phosphorylation depended, at least partially, on the p38 phosphatase, Wip1. Expression of LZAP
increased both LZAP and Wip1 binding to p38. Taken together, these data suggest that LZAP activity includes inhibition of
p38 phosphorylation and activation.
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Introduction
LZAP (Cdk5rap3, C53) was originally identified as a binding
partner of the Cdk5 activator p35 [1], but insight into LZAP
activity was gained when it was found to bind the alternate reading
frame protein of the INK4a gene locus, ARF (p14
ARF in human
and p19
ARF in mice) and activate p53, both in the presence and
absence of ARF, resulting in a G1 cell cycle arrest and inhibition
of clonogenic growth [2]. Further, LZAP inhibits cellular
transformation, xenograft tumor growth, and xenograft tumor
vascularity at least partially through LZAP’s ability to bind and
inhibit RelA [3]. Evidence of a tumor suppressor-like role for
LZAP was bolstered when LZAP protein levels were found to be
markedly decreased in head neck squamous cell carcinoma
(HNSCC) where its loss inversely correlates with expression of
NF-kB target genes [3]. LZAP also inhibits the checkpoint kinases
(Chk1 and Chk2), promotes mitotic entry and, in the presence of
DNA damaging agents, sensitizes to cell death [4,5]. Further
exploration of LZAP regulation found that a binding partner of
LZAP, RCAD/NLBP, stabilizes LZAP protein levels and loss of
RCAD/NLBP results in loss of LZAP with enhanced NF-kB
signaling and cell invasion [6,7]. Collectively, these data are
consistent with a role for LZAP in tumor suppression.
p38MAPK belongs to a family of stress-activated MAPKs that
responds to cellular stress and cytokines. Expression patterns
suggest that p38a may be the primary p38 kinase in most cell types
[8]. Activity of p38 reflects a balance between the upstream
activating kinases (MKK3 and MKK6) and inactivating protein
phosphatases, primarily the wild-type p53-induced phosphatase 1
(Wip1, PPM1D, PP2Cd) [9–10]. p38 activity results in pleiotropic
downstream cellular and tissue effects including: cytokine
production, inflammation, cellular differentiation, cell-cycle arrest,
apoptosis, and senescence [8,11,12,13,14,15]. Given the roles of
p38 as an inducer of apoptosis and inhibitor of cellular
proliferation, it is ironic that elevated p38 expression has been
found in many cancer types, including breast, lung, thyroid and
HNSCC, and that p38 has been implicated in promoting cell
survival [12,16,17,18,19]. Given the conflicting cellular effects that
can result from p38 activation, the role of p38 in human cancer as
a tumor promoter or a tumor suppressor likely depends on tumor
and cell specific context [8].
Here, we describe that the putative tumor suppressor LZAP
bound and inhibited p38MAPK. Conversely, depletion of LZAP
enhanced phosphorylation and activity of p38. LZAP did not alter
p38 activating kinases (MKKs); however, LZAP increased
association of p38 with Wip1 and LZAP dependent inhibition of
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16427p38 phosphorylation was at least partially dependent on Wip1.
Given that LZAP inhibits p38 activity and that the role of p38 in
cancers can vary from growth inhibitory to growth promoting,
results presented here suggest that LZAP activities in tumors may
be complex.
Results
LZAP interacts with p38 MAPK in vivo
Described LZAP activities include inhibition of cellular
proliferation, inhibition of anchorage-independent growth, and
enhancement of response to chemotherapeutic agents [2,4,5].
LZAP expression is lost in a subset of human HNSCC and loss of
LZAP in xenograft tumors enhances tumor growth and angio-
genesis [3]. These data suggest that LZAP may function as a
tumor suppressor. Intriguingly, morpholino directed loss of LZAP
expression in zebrafish resulted in cell death and developmental
delay (data not shown). Combined, these data suggest that either
increased or decreased LZAP levels may have detrimental effects
on cell survival. To identify proteins that may contribute to
biological activities of LZAP, we screened human LZAP amino
acid sequence for motifs recognized by modular signaling domains
using the Scansite algorithm [20]. Using high stringency criteria,
Scansite analyses suggested that LZAP contained motifs predicted
to bind 14-3-3-zeta and the docking domain (D domain) of
mitogen activated protein kinases (MAPKs) (Table S1). Because D
domain-dependent interactions are essential for MAPK binding to
upstream regulators and downstream mediators [21] and because
p38 and LZAP have been shown to activate p53 and to interact
physically or functionally with Chk1, p38 was chosen for further
exploration [12] [22] [2].
To confirm the predicted interaction between LZAP and p38,
Myc-tagged LZAP was transiently expressed singly or with Flag-
tagged p38 in mammalian U2OS cells before immunoprecipita-
tion. When co-expressed, bands corresponding to Myc-tagged
LZAP and untagged LZAP were detected in p38 immunoprecip-
itates (Fig. 1A, lane 2, top panel). Likewise, p38 was readily
detected in LZAP immuno-precipitates (Fig. 1A, lane 4, top panel).
Expressed LZAP was also detected in immunoprecipitates of
endogenous p38; however, endogenous p38 could not be detected
in LZAP immunoprecipitates following LZAP expression (Fig. 1A,
lanes 1 and 3, top panels). Expression of proteins was confirmed
(bottom panels) and non-immune mouse IgG (middle panels) was
used as a control for non-specific immunoprecipitation. To
determine if endogenous p38 and LZAP associated in mammalian
cells, co-immunoprecipitation of LZAP and p38 was performed
using asynchronously growing MCF7 cells, in which LZAP and
p38 expression levels are relatively higher compared to U2OS cells
(data not shown). p38 was detected in LZAP immunoprecipitates
either with or without UV irradiation, but not in precipitates using
non-immune rabbit IgG (Fig. 1B, compare lanes 3 and 4 to lanes 5
and 6, the arrow indicates p38). Reciprocal immunoprecipitation
using p38-specific antibody did not allow detection of LZAP (data
not shown). These data suggest that expressed and endogenous
LZAP and p38 exist in a common complex.
To determine if LZAP and p38 co-localized or altered one
another’s subcellular localization, immunofluorescent staining of
LZAP and p38 were performed following single or combined
transient expression (Fig. 1C). When expressed without p38, LZAP
localizes to both the nucleus and cytoplasm, but is excluded from
nucleoli as previously described (data not shown and [3] [2]). In
the absence of LZAP, expressed p38 localized to both the
cytoplasm and nucleoplasm with more than 60% of cells showing
stronger localization to the peri-nuclear region (Fig. 1C, top panel
arrows). LZAP localization was not altered by co-expression of
p38; however, co-expression of LZAP with p38 resulted in a shift
of p38 staining from predominantly peri-nuclear to predominantly
nuclear (Fig. 1C, p38 stained panels and graph, p,0.0001).
To confirm the observation that LZAP altered p38 subcellular
localization, cellular fractionation was performed on cells express-
ing p38 with and without LZAP. As expected, both p38 and LZAP
localized to both the nuclear and cytoplasmic fractions; however,
expression of LZAP increased the amount of p38 detected in the
nuclear fraction (Fig. 1D). Fidelity of the nuclear and cytoplasmic
fractions was confirmed by expression of nucleolin/C23 and b-
actin. Combined, immunofluorescence and cellular fractionation
data suggest that LZAP and p38 co-localize and that expression of
LZAP increases p38 nuclear localization.
To begin defining regions of LZAP required for p38 interaction,
LZAP truncation mutants were co-expressed with full length p38
before co-immunoprecipitation (Fig. 2). Results following either
p38 or LZAP immunoprecipitation revealed that an extended
LZAP amino terminus region (aa1-303) was sufficient for binding
to p38. Within the amino terminal region of LZAP, aa 1-111 was
unable to bind p38, suggesting that aa 112-303 were required for
this binding. A separate and non-overlapping extended carboxy
terminal region of LZAP (aa 329-506) was also sufficient for p38
binding. Truncation of the extended carboxy terminal region
abrogated p38 binding suggesting that aa 329-359 of LZAP are
required for p38 binding; however, amino acids 329-359 of LZAP
were not sufficient for binding to p38 because a central LZAP
truncation containing this region (aa 201-358) failed to bind.
Within the central region, an LZAP fragment containing residues
112-358 was capable of binding p38 suggesting that a critical
domain for p38 binding exists between amino acids 112 and 201 of
LZAP (Fig. 2). Results of these p38 binding experiments using
LZAP truncations are summarized (Fig. 2).
LZAP inhibits phosphorylation of p38
MAPK family members are activated by phosphorylation and
upon activation are translocated from the cytoplasm to the nucleus
[23,24,25]. The dramatic relocalization of p38 from predomi-
nantly perinuclear to predominantly nuclear in the presence of
LZAP (Fig. 1C and 1D) suggests that LZAP may alter p38 activity.
To begin exploring effects of LZAP on p38 activity, total and
phosphorylated p38 were detected following transient expression
of p38 with or without increasing amounts of Myc-LZAP (Fig. 3A).
Expression of LZAP decreased the amount of phospho-p38
detected in a dose dependent fashion, but did not alter total p38
levels. As expected, the amount of LZAP found in p38 immune-
complexes increased as LZAP expression increased (Fig. 3A,
bottom panel).
Expression of LZAP was associated with increased nuclear p38
levels, but surprisingly, LZAP was also found to decrease total
cellular phospho-p38 levels (Fig. 1C, 1D, and 3A). To determine
if nuclear p38 was phosphorylated in the presence of LZAP,
immunofluorescent staining of p38, phospho-p38, and LZAP was
performed following transient expression of Flag-p38 with or
without Myc-LZAP and activation of p38 using UV irradiation
(20 J/m
2). Consistent with our previous findings, LZAP expres-
sion increased nuclear localization of p38 as indicated by
immunofluorescence (Fig. 3B, lower panel green). Despite its
ability to increase levels of nuclear p38, LZAP strongly inhibited
accumulation of nuclear phospho-p38 following UV irradiation
(Fig. 3B, compare upper and lower red panels). Quantification of
phospho-p38 results revealed that 48% of p38 expressing cells
were positive for nuclear phospho-p38 in the absence of
expressed LZAP, compared to only 11% of p38 expressing cells
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LZAP (Fig. 3B, p,0.0001). Regardless of LZAP expression,
cytoplasmic phospho-38 was not detected. Data represent
examination of more than 100 cells from 3 independent
experiments. Combined, these data suggest that LZAP inhibits
phosphorylation of nuclear p38.
Depletion of endogenous LZAP activates p38
To determine if endogenous LZAP regulates p38, LZAP was
depleted by siRNA and p38 phosphorylation determined.
Knockdown of LZAP in U2OS cells did not alter p38 expression;
however, loss of LZAP was associated with increased levels of
phospho-p38 levels in either the presence or absence of activating
Figure 1. LZAP binds to p38. (A) Ectopically expressed LZAP and p38 mutually co-immunoprecipitate. U20S cells were transfected with indicated
plasmids directing expression of tagged LZAP or p38. Immunoprecipitates were prepared using mouse antibodies recognizing Myc (LZAP) or p38,
resolved on SDS-PAGE, and immunoblotted by rabbit antibodies recognizing LZAP or p38. Expression of LZAP and p38 was confirmed by
immunoblotting (1% of each input lysate was loaded as reference.) Pre-immune IgG was used to control for non-specific immunoprecipitation. (B)
Endogenous LZAP binds endogenous p38. Lysates from untransfected MCF7 cells without or with UV irradiation (20 J/m
2) were immunoprecipitated
using LZAP-specific rabbit antiserium or non-immune rabbit IgG, then immunoblotted with antibodies specific to p38 or LZAP as indicated. (C) LZAP
co-localizes with p38 and alters p38 subcellular localization. U2OS cells were transfected with plasmids directing expression of Flag-p38 with or
without LZAP. Cells were fixed and p38 and LZAP expression and localization determined by indirect immunofluorescence using anti-Flag
monoclonal antibody and affinity-purified rabbit anti-LZAP antibody. Cytoplasmic, nuclear and peri-nuclear localization of p38 was determined by
direct visualization and quantified based on at least 100 cells from at least 3 independent experiments. The shift of p38 localization from perinuclear
region to nucleus was statistically significant (p,0.0001, using unpaired 2 tailed t test). (D) Increased p38 abundance in the nuclear following LZAP
co-expression. U2OS cells were transfected with plasmids directing expression of Flag-p38 with or without LZAP. Whole cell, cytoplasmic and nuclear
cell lysate were prepared, then immunoprecipitates from each lysate were prepared using anti-Flag M2 affinity gel, resolved on SDS-PAGE, and
immunoblotted by rabbit p38 antibody. The levels of C23 (nucleolar protein) and b-actin (cytoplasmic protein) were used to monitor the quality of
the fractionation and the even loading of samples (1% of each input lysate was loaded as reference.). Expression of LZAP was confirmed by
immunoblotting (1% of each input lysate was loaded as reference.), endogenous LZAP could be detected after longer exposure.
doi:10.1371/journal.pone.0016427.g001
LZAP Inhibits p38 through WIP1
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16427cytokines, TNFa and IL-1b (Fig. 3C). LZAP loss following siRNA
treatment was confirmed and GAPDH was used as a loading
control (Fig. 3C). Off target effects of siRNA were explored by
simultaneous siRNA mediated knockdown and expression of
LZAP containing silent mutations within the targeting siRNA
sequence (RNAi-insensitive LZAP). As described above, cells were
treated with TNFa to activate p38 resulting in robust phospho-p38
signal following LZAP knockdown (Fig. 3D, lane 1). Regardless of
transfection with siRNA targeting LZAP, expression of RNAi-
insensitive LZAP resulted in marked inhibition of phospho-p38
levels (Fig. 3D, lanes 2 and 3). To determine if LZAP activity was
cell type specific, p38 phosphorylation after LZAP knockdown and
IL-1b stimulation was determined in 1 breast cancer cell line
(MCF-7) and in 2 head and neck squamous cell carcinoma lines
(UM-SCC47, FaDu).As observed in U2OS cells, siRNA-mediated
loss of LZAP was associated with increased p38 phosphorylation
(Fig. 3E). Taken together, these data suggest that endogenous
LZAP alters p38 phosphorylation both in the presence or absence
of activating cytokines.
Upstream MAPK kinases (MKK3 or MKK6) activate p38
through direct phosphorylation at thr180 and tyr182 [26]. Once
activated, p38 phosphorylates downstream target proteins includ-
ing: MAPKAPK2 and the transcription factor ATF2. To
determine if increased p38 phosphorylation observed upon loss
of endogenous LZAP correlates with p38 kinase activity,
phosphorylation of p38 target proteins) was measured in the
presence or absence of siRNA targeting LZAP (Fig. 4A). After
cytokine or LPS stimulation, knockdown of LZAP resulted in
increased phosphorylation of p38 targets ATF2 and MAPKAPK2.
MAPKAPK2 is itself a kinase that directly phosphorylates HSP27.
siRNA-mediated loss of LZAP was associated with increased
HSP27 phosphorylation suggesting that a kinase cascade down-
stream of p38 was activated upon LZAP loss. To begin exploring
potential mechanisms of LZAP activity toward p38, the effect of
LZAP loss on MKK3 and MKK6 phosphorylation was deter-
mined. LZAP knockdown was not associated with increased
phosphorylation of upstream p38 kinases, MKK3 or MKK6
(Fig. 4A). Decreased LZAP expression was confirmed by
immunoblotting following siRNA treatment (data not shown).
p38-mediated phosphorylation of ATF2 activates ATF2 tran-
scriptional activity [27]. In the presence of cytokines, loss of LZAP
expression was associated with increased ATF2 phosphorylation
(Fig. 4A), suggesting that LZAP expression may inhibit ATF2
transcriptional activity. To explore this possibility, a luciferase
reporter system relying on a chimeric transcription factor
construct containing the GAL4 DNA binding domain fused to
ATF2 transcriptional activating domain was used as a surrogate
for measurement of ATF2 transcriptional activity [28]. In the
presence of p38, expression of LZAP resulted in a dose-dependent
decrease in ATF2 transcriptional activity (Fig. 4B). Data represent
3 independent experiments. Taken together, these data suggest
that phosphorylation and activity of p38 and downstream p38
targets are inhibited by endogenous LZAP and that upstream
MKKs are not mediating LZAP activity toward p38.
LZAP alters Wip1 association with p38
Loss of LZAP did not result in activation of upstream p38-
activating kinases MKK3 or MKK6 (Fig. 4A), suggesting that
LZAP-mediated inhibition of p38 occurred through alternate
mechanisms. Activity and phosphorylation of p38 reflects a
Figure 2. Independent and non-overlapping areas of LZAP are sufficient for association with p38. U2OS cells were transfected with
plasmids directing expression of Myc3-tagged truncation mutants of LZAP and full-length Flag-tagged p38. P38 was immunoprecipitated using anti-
Flag and LZAP truncation mutants were immunoprecipitated using anti-Myc antibodies before immunoblotting with anti-Myc to detect LZAP
truncations or anti-p38. Expression of LZAP truncation mutants was confirmed by immunoblotting and binding activity of LZAP truncation mutants is
schematically summarized.
doi:10.1371/journal.pone.0016427.g002
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plasmids encoding Flag-p38 and with or without increasing amounts of Myc3-LZAP plasmid as indicated. p38 was immunoprecipitated using anti-
Flag antibody and p38 phosphorylation at Thr180/Tyr182 determined by immunoblotting. Levels of p38 and LZAP in p38 immunoprecipitates were
determined by immunoblotting with antibodies recognizing p38 or LZAP as described [2]). (B) LZAP inhibits accumulation of phosphorylated p38 in
the nucleus. U2OS cells were transfected with plasmids directing expression of Flag-p38 with or without Myc3- LZAP. After UV irradiation (20 J/m
2),
cells were triply immunostained with anti-phopho-p38, anti-Flag, and anti-Myc. The fraction of p38 expressing cells with detectable phosphorylated
p38 was determined by direct visualization. Expression of LZAP was associated with a significant decrease in detection of phosphorylated p38 in p38
expressing cells ((p,0.0001, using unpaired 2 tailed t test). Data are derived from examination of at least 200 cells from at least three independent
experiments. (C) Depletion of LZAP increases phosphorylation of p38 in U2OS cells. U2OS cells were transiently transfected with control siRNA or
siRNA specific to LZAP. Activating phosphorylation of p38 at Thr180/Tyr182 was determined in untreated cells or in cell treated with TNFa or IL-1b by
immunoblotting. Expression of LZAP and total p38 was confirmed and GAPDH was used as a loading control. (D) Depletion of the LZAP protein
correlates with p38 activation. Twenty-four hours after transfection with control siRNA or siRNA targeting LZAP, U2OS cells were transfected with
plasmid encoding RNAi-insensitive LZAP. Transfected cells were selected with G-418 stimulated using TNFa and p38 phosphorylation determined by
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protein phosphatases. Wip1 is a nuclear protein phosphatase that
was found to be expressed in response to p53 and to complete a
negative feedback loop through inhibition of p53 [29]. In addition
to its role in abrogating p53 activity, Wip1 was found to form a
physical complex with p38 in vivo and to directly dephosphorylate
and inactivate p38 [10,29,30,31,32].
To determine if the Wip1 phosphatase was involved in LZAP’s
inhibition of p38, binding of Wip1 to p38 was determined
following transient expression of p38 singly or with increasing
expression of LZAP. Before p38 immunoprecipitation, cells were
UV treated to increase p38 phosphorylation and expression of
endogenous Wip1 [10,33]. Wip1 was not detected in p38
immunoprecipitates in the absence of LZAP (Fig. 5A, lane 2);
however, as LZAP expression increased Wip1 association with p38
became detectable and increased concordant with LZAP expres-
sion (Fig. 5A, lanes 3–5). In agreement with our earlier findings
(Fig. 3A), LZAP expression had no effect on p38 expression;
however, increased expression of LZAP correlated with detection
of LZAP in p38 immunoprecipitates (Fig. 5A).
Expression of LZAP resulted in increased association between
p38 and its direct phosphatase, Wip1, suggesting that decreased
phosphorylation and activity of p38 following LZAP expression
may be mediated by Wip1. To explore this possibility, phosphor-
ylation of p38 was compared following transient expression of
LZAP with or without siRNA mediated inhibition of Wip1
expression. As expected, expression of LZAP resulted in decreased
p38 phosphorylation (Fig. 5B, top panel compare lanes 1 and 2).
In the presence of LZAP, loss of Wip1 expression restored p38
phosphorylation suggesting that LZAP-mediated inhibition of p38
phosphorylation was at least partially dependent on Wip1 (Fig. 5B).
Increased p38 phosphorylation following Wip1 loss in the absence
of expressed LZAP has been previously demonstrated [32,34] and
was confirmed in U2OS cells following transfection of siRNA
targeting Wip1 (Fig. 5B, right panel).
Discussion
Based on loss of expression in human HNSCC and cellular
effects associated with loss of LZAP such as enhanced invasion,
anchorage independent growth, angiogenesis, and growth of
xenograft tumors, LZAP has been identified as a putative tumor
suppressor [3]. LZAP contains no enzymatic motifs suggesting that
its activities may be derived through protein-protein interactions.
A remarkable number of molecules that are implicated in
tumorigenesis (e.g. ARF, RelA, Chk1, Chk2, and as described
here p38) have been found to bind to LZAP suggesting that LZAP
activity may be protean [2,3,4,5]. Although identification of
binding partners has provided insight into LZAP function,
satisfying mechanisms of pleiotropic LZAP activities have been
lacking.
Here we report that LZAP bound to the stress activated protein
kinase p38, altered p38 subcellular localization and inhibited p38
phosphorylation and activity. Mechanistically, our data suggest
that LZAP inhibition of p38 phosphorylation depends on the
Wip1 phosphatase, and that in the presence of LZAP, more Wip1
immunoblotting. Immunoblotting confirmed expression of p38 and si-RNA insensitive LZAP as described [2]. Immunoblotting of GAPDH served as
control. (E) Depletion of LZAP increases phosphorylation of p38 in other cell types. MCF7, UM-SCC47 and FaDu cells were transiently transfected with
control siRNA or siRNA specific to LZAP. Activating phosphorylation of p38 at Thr180/Tyr182 was determined in cells treated with IL-1b by
immunoblotting. Expression of LZAP and total p38 was confirmed and GAPDH was used as a loading control.
doi:10.1371/journal.pone.0016427.g003
Figure 4. Loss of LZAP increases p38 kinase activity, but does not alter MKK activation. (A) Depletion of LZAP increases phosphorylation
of p38 targets, but does not alter phosphorylation of MKK3/MKK6. U2OS cells were transfected with control siRNA or siRNA targeting LZAP before
stimulation with TNFa, IL-1b, or LPS. Phosphorylation of direct or indirect p38 targets ATF2, MAPKAPK2, HSP27 and activators of p38, MKK3 and
MKK6, was visualized by immunoblotting. LZAP knockdown was confirmed by immunoblotting and expression of GAPDH was used as a loading
control. (B) LZAP inhibits transcriptional activity of the p38 target ATF2. U2OS cells were transfected with plasmids directing expression of GAL-ATF2
and p38, with or without increasing amounts of LZAP along with a luciferase reporter containing the GAL DNA binding sequence, as indicated. Firefly
luciferase activity was normalized based on renilla luciferase activity and assigned a value of 1 in cells without transfected LZAP. All normalized
luciferase assay data are expressed as the mean with the standard error and are the result of the least three independent experiments.
doi:10.1371/journal.pone.0016427.g004
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the nucleus in a complex with Wip1 as a means of p38
inactivation. Alternatively, unphosphorylated nuclear p38 may
have unknown activities or may be sequestered in the nucleus so
that upon loss of LZAP, rapid activation of p38 could occur
through phosphorylation by nuclear kinases.
Interestingly, LZAP was found to bind p38 through two
independent and non-overlapping domains, an amino-terminal
region (aa 1-303), and a carboxy-terminal region (aa 329-506) of
LZAP. Based on gel filtration, LZAP has been reported to exist in
large molecular weight complexes and the pattern of independent
regions of LZAP binding to its partners, as we observed, has been
reported and may be critical for formation of large protein
complexes containing LZAP [6]. It is possible that physical
association between independent regions of LZAP and its binding
partners are integral to LZAP function; however, we and others
have found that LZAP can bind to itself suggesting that
dimerization or oligomerization of LZAP could explain detection
of multiple independent binding sites within LZAP (data not
shown and [6]).
The mechanism of LZAP activity toward the growing list of
LZAP-associated proteins (LAPs) is not well understood. LZAP has
no described enzymatic activity, suggesting that LZAP may exert
its effects through association with other proteins. The finding that
a portion of LZAP exists in large molecular weight complexes
combined with a potential for LZAP to oligomerize lends credence
to this argument and further suggests that LZAP may serve to
bring together effector proteins. A large portion of LZAP
interacting proteins are phosphorylated, and LZAP expression
has been associated with decreased phosphorylation of these
proteins. These observations led us to explore if LZAP had activity
to inhibit p38 upstream kinases or to activate p38 phosphatases.
We found that LZAP did not alter kinase activity, as measured by
phosphorylation, of MKK3 or MKK6; however, LZAP was found
to increase association of p38 with its direct phosphatase Wip1
(Fig. 5A). It is unclear if regulation of phosphatases is a general
mechanism of LZAP activity, but it is clear that it is not a universal
mechanism since phosphorylation has not been described to play a
role in LZAP-mediated ARF activity. It is intriguing that
additional described LAPs including RelA, Chk1 and Chk2 are
also targets of phosphatases, including Wip1 [31,35,36]. We have
previously shown that LZAP activates p53 in the absence of ARF
raising the possibility that this ARF-independent activity of LZAP
may also depend on Wip1 [2].
Depending on cellular context, p38 can mediate opposing
cellular responses as an inducer or inhibitor of proliferation and
apoptosis [8]. To date, most data highlights LZAP as a tumor
suppressor [2,3,4,5,7], but its role as a p38 regulator imply that
LZAP could also have opposing cellular effects or that LZAP
inhibition of p38 could be restricted to circumstances where
inhibition of p38 suppresses tumor promoting activity.
Materials and Methods
Plasmid constructs
The full coding sequence and truncation mutants of LZAP were
subcloned into pcDNA3-Myc3 and pET-His expression vectors
[2,3]. Plasmids Flag-p38a and Gal-ATF2 were generous gifts from
Dr. Jiahuai Han (The Scripps Research Institute, La Jolla, CA).
LZAP that was not a target of siRNA-2(sense strand: 59-
CAAGGTATGTGGACCGAGT) [3] was constructed by intro-
ducing the silent mutations G294A and G297A in pCI-Neo-
LZAP.
Antibodies and Reagents
LZAP polyclonal rabbit antibody has been previously described
[2]; Mouse monoclonal antibody were purchased as follows: Flag
(M2), and anti-Flag M2 affinity gel (Sigma); mouse monoclonal
antibodies specific to Myc (9E10), p38 (A-12), rabbit GAPDH,
normal mouse and Rabbit IgG, and secondary mouse and rabbit
antibodies (Santa Cruz Biotechnology); rabbit polyclonal to p38
(Abcam); Wip1 rabbit polyclonal antibody (Bethyl); flurophore-
conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories); chicken anti-human Myc-tag polyclonal antibody
(Thermo Scientific); and all other antibodies (Cell Signaling).
TNFa, IL-1b, and LPS were purchased from PeproTech.
Cell culture and transfection
Cell lines were maintained at 37uC with 5% CO2, in growth
media with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad,
CA). Cell lines were obtained from ATCC or collaborators and
have been passed in the Yarbrough lab with biannual authenti-
Figure 5. LZAP regulation of p38 phosphorylation involves
Wip1. (A) LZAP increases Wip1 association with p38. U2OS cells were
transfected with plasmids directing expression of Flag-p38 with or
without increasing amounts of myc-LZAP as indicated. Immunoprecip-
itation of Flag-tagged p38 was followed by immmunoblotting using
antibodies specific to Wip1, or p38. (B) Wip1 is required for inhibition of
p38 phosphorylation directed by LZAP. U2OS cells were transfected
with control siRNA or siRNA targeting Wip1, and after 1 day co-
transfected with Flag-p38 with and without Myc3-LZAP, as indicated.
Phosphorylation of p38 was visualized by immunoblotting after Flag-
p38 immunoprecipitation. Immunoblotting was used to confirm
expression of p38 and GAPDH as an indicator of loading.
doi:10.1371/journal.pone.0016427.g005
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(D7S1482A, Mycl1A and DXS981C). Plasmids were transfected
using FuGene6 (Roche, Indianapolis, IN) according to the
manufacturer’s instructions. The total amount of transfected
DNA in any single experiment was kept constant by adding
control vector (pcDNA3). Small interfering RNA (siRNA) was
transfected at 20 nM using Lipofectamine RNAiMAX (Invitro-
gen, Carlsbad, CA). Control siRNA duplex (nontargeting #1) was
purchased from Dharmacon (Dharmacon, Chicago, IL). The
LZAP siRNA-2 was previously described [3] with on-TARGET-
plus modification, 59-CAAGGTATGTGGACCGAGT (sense
strand); the sequence of Wip1 siRNA is: 59- GGCUUUCUCG-
CUUGUCACC dTdT [37] purchased from Dharmacon.
Immunoprecipitation and immunoblotting
Cells were lysed in 0.5%(v/v) Nonidet P40 lysis buffer [38]
supplemented with protease inhibitor cocktail (Roche). Total cell
extracts were incubated with specific antibodies and precipitated
with protein A or G sepharose beads (GE Healthcare) before
washing and suspension in Laemmli and gel electrophoresis
followed by immunoblotting as described [39]
Immunofluorescence assay
Briefly, cells were fixed with paraformaldehyde permeabilized
with Triton X-100, and blocked with BSA. Target proteins were
visualized following incubation with primary antibodies followed
by fluorophore secondary antibodies and visualization as described
[40].
Cell fractionation
Cells were scraped in cytosolic lysis buffer (10 mM Tris-HCl
[pH 7.5], 100 mM NaCl, 2.5 mM MgCl2, and 40 mg/ml
digitonin). The lysate was incubated on ice for 5 min and
centrifuged (2100 g, 8 min, 4uC), and the supernatant was
designated as soluble cytosolic fraction. The pellet was washed
with the same buffer before adding RIPA lysis buffer (10 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.1%
SDS, and 1 mM DTT), incubated on ice for 5 min and
centrifuged (14,000 rpm, 10 min, 4uC), to obtain the nuclear
fraction. Whole cell lysates were prepared using RIPA buffer, as
described [41].
Luciferase reporter assay
ATF2 reporter gene assay was performed using the Dual-
Luciferase Reporter Assay System (Promega) as described [3].
Reporter constructs were co-transfected into U2OS cells main-
taining equal plasmid amounts. Luciferase activity was measured
24 hours after transfection following the manufacturer’s instruc-
tions. Luciferase activity was normalized to renilla activity as a
control of transfection efficiency.
Supporting Information
Table S1 LZAP predicted motifs from Scansite. LZAP
protein coding sequence was inputed for motif scan, and chose
high stringency criteria to look for all possible binding motifs.
(TIF)
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